How End of Life Is the Real Healthcare Crisis By Craig Hasday I am seeing, first hand, rampant and uncontrollable costs related to end of life in a system that lacks any semblance of common sense.
A Radical Shift in Pricing Cancer Drugs? By Tom Emerick Cancer drugs have become extraordinarily expensive even though many provide little benefit. Shouldn't prices reflect benefits?
Better Approach to Soft Tissue Injury By MaryRose Reaston Frank Tomecek Soft tissue injury is extremely common but hard to diagnose and subject to unnecessary and expensive treatment. EFA provides a better tool.
$1 Million Reward to Show Wellness Works By Al Lewis Vik Khanna We'll settle the wellness debate the old-fashioned way: offering a $1 million reward to anyone who can prove it isn't a horrible investment.
Confessions of Sleep Apnea Man By Bob Wilson Elements of medical care in the U.S. just plumb confound me. One is the requirement of a prescription for the most mundane of items.
The iDoctor Will See You Now By Tom Emerick Via iDoctor, huge numbers of tests can be done more cheaply and faster and could be much less wasteful in terms of patients’ time.
More Pressure to Protect Health Data By Cynthia Marcotte Stamer The federal government is demanding better security for personal health data, and those operating health plans must react.
Doubts on Testing for Breast Cancer By Tom Emerick Early studies on using mammograms to screen for breast cancer were deeply flawed, largely because they can lead to over-diagnosis.
Auto Insurance in an Existential Crisis By Stephen Applebaum Alan Demers The 125-year-old, $300 billion U.S. auto insurance industry is caught between runaway inflation and strained consumer wallets.
The Promise of Continuous Underwriting By Bill Deemer Bobby Touran Typically, a risk is underwritten, bound... and forgotten. But new streams of data and automation allow for continuous underwriting.
Convergence and the Insurance Ecosystem By Stephen Applebaum Alan Demers Companies must anticipate the future, innovate beyond their core and transform their capabilities as rapidly as technology allows.
Lemonade's 'Synthetic Agent' Nonsense By Matteo Carbone Desperate for growth, Lemonade produces another howler: A lender receiving a 16% interest rate is presented as a (synthetic) agent.